European Journal of Cancer
Volume 37, Issue 3 , Pages 355-363 , February 2001

CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases

  • M Gion

      Affiliations

    • Center for the Study of Biological Markers of Malignancy, General Regional Hospital, ULSS 12, Venice, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-041-5294535; fax: +39-041-5294653
    • ,
  • R Mione

      Affiliations

    • Center for the Study of Biological Markers of Malignancy, General Regional Hospital, ULSS 12, Venice, Italy
    • ,
  • A.E Leon

      Affiliations

    • Center for the Study of Biological Markers of Malignancy, General Regional Hospital, ULSS 12, Venice, Italy
    • ,
  • D Lüftner

      Affiliations

    • Medizinische Klinik und Poliklinik II Schwerpunkt Onkologie und Hämatologie Universitätsklinikum Charité, Campus Mitte Humboldt, Universität Berlin, Germany
    • ,
  • R Molina

      Affiliations

    • Laboratory of Clinical Biochemistry, Unit for Cancer Research, Hospital Clinico Provincial, Barcelona, Spain
    • ,
  • K Possinger

      Affiliations

    • Medizinische Klinik und Poliklinik II Schwerpunkt Onkologie und Hämatologie Universitätsklinikum Charité, Campus Mitte Humboldt, Universität Berlin, Germany
    • ,
  • J.F Robertson

      Affiliations

    • Professorial Unit of Surgery, Faculty of Medicine and Health Science, City Hospital, Nottingham, UK

Received 30 May 2000 ,Revised 15 September 2000 ,Accepted 2 November 2000.

References 

  1. American Society of Clinical Oncology . Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J. Clin. Oncol. 1996;14:2843–2877
  2. American Society of Clinical Oncology . 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J. Clin. Oncol. 1998;16:793–795
  3. Molina R, Duffy MJ, Aronsson AC, Lamerz R, Stieber P, van Dalen H. Tumour markers in breast cancer. EGTM recommendations. Anticancer Res. 1999;19:2803–2805
  4. Molina R, Zanon G, Filella X, et al.  Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients.. Breast Cancer Res. Treat. 1995;36:41–48
  5. Molina R, Jo J, Zanón G, et al.  Utility of c-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients (comparison with carcinoembryonic antigen and CA 15.3). Br. J. Cancer. 1996;74:1126–1131
  6. Robertson JFR, Jaeger W, Syzmendera JJ, et al.  The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. Eur. J. Cancer. 1999;35:47–53
  7. Shering SG, Sherry F, Mcdermott EW, O'Higgins NJ, Duffy MJ. Preoperative CA 15-3 concentration predict outcome of patients with breast carcinoma. Cancer. 1998;83:2521–2527
  8. Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival by ‘early’ salvage treatment of breast cancer patients (a retrospective 6-year study). Br. J. Cancer. 1997;76:1106–1111
  9. Fleming TR, DeMets DL. Surrogate end points in clinical trials (are we being misled?). Ann. Inter. Med. 1996;125:605–613
  10. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M. MUC1 and cancer. Biochim. Biophis. Acta. 1999;1455:301–313
  11. Agrawal B, Gendler SJ, Longenecker BM. The biological role of mucins in cellular interactions and immune regulation (prospects for cancer immunotherapy). Mol. Med. Today. 1998;4:397–403
  12. Roth HJ, Zahn I, Maimonis P. Performance characteristics of the ACS-BR (a comparison with three other assays that also measure CA15.3). Clin. Lab. 1995;41:1031–1035
  13. Beveridge RA. Review of clinical studies of CA27.29 in breast cancer management. Int. J. Biol. Markers. 1999;14:36–39
  14. Correale M, Abbate I, Gargano G, et al.  Analytical and clinical evaluation of a new tumor marker in breast cancer: CA27.29. Int. J. Biol. Markers. 1992;7:43–46
  15. Rodriguez De Paterna L, Arnaiz F, Estenoz J, Ortuno B, Lanzos E. Study of serum tumor markers CEA, CA15.3 and CA27.29 as diagnostic parameters in patients with breast carcinoma. Int. J. Biol. Markers. 1995;10:24–29
  16. Aspeslet L, Ballok J, Mansbach L, Maimonis PJ. A Technical and clinical evaluation of 3 commercial MUC1 breast cancer marker assays. Tumor Biol. 1998;19:13
  17. Chan DW, Beveridge RA, Muss H, et al.  Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J. Clin. Oncol. 1997;15:2322–2328
  18. Bon GG, von Mensdorff-Pouilly S, Kenemans P, et al.  Clinical and technical evaluation of ACS(TM)BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays. Clin. Chem. 1997;43:585–593
  19. Lynch DM, Rogers PE, Love JC, et al.  Clinical evaluation comparing AxSYM (R) CA 15-3 (TM), IMx (R) CA 15-3 and Truquant (R) BR (TM) RIA. Tumor Biol. 1998;19:421–438
  20. Hou MF, Chen YL, Tseng TF, et al.  Evaluation of serum CA27.29, CA15.3 and CEA in patients with breast cancer. Kao. Hsiung. I. Hsieh. Ko. Hsueh. Tsa. Chih. 1999;15:520–528
  21. Gion M, Mione R, Leon AE, Dittadi R. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clin. Chem. 1999;45:630–637
  22. Zucchell GC, Pilo A, Chiesa MR, et al.  Analytical performance of CA19.9, CA125 and CA15.3 assays as observed through an external quality assessment program. Int. J. Biol. Markers. 1994;9:43–47
  23. Duffy MJ. CA 15.3 and related mucins as circulating markers in breast cancer. Ann. Clin. Biochem. 1999;36:579–586
  24. Graves R, Hilgers J, Fritsche H, Hayes D, Robertson JFR. MUC-1 mucin assays for monitoring therapy in metastatic breast cancer. Breast. 1998;7:1–6
  25. Price MR, Rye PD, Petrakou E, et al.  Summary report on the ISOBM TD-4 workshop (analysis of 56 monoclonal antibodies against the MUC1 mucin). Tumor Biol. 1998;19:1–20
  26. Bombardieri E, Gion M, Mione R, Dittadi R, Bruscagnin G, Buraggi GL. A mucinous-like carcinoma-associated antigen (MCA) in the tissue and blood of patients with primary breast cancer. Cancer. 1989;63:490–495
  27. Gion M, Plebani M, Mione R, Penzo C, Meo S, Burlina A. Serum CA549 in primary breast cancer (comparison with CA 15.3 and MCA). Br. J. Cancer. 1994;69:721–725
  28. Hounsell EF, Young M, Davies MJ. Glycoprotein changes in tumours (a renaissance in clinical applications). Clin. Sci. 1997;93:287–293
  29. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J. Cell. Biol. 1995;129:255–265
  30. Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol. Biol. Cell. 1996;7:565–577
  31. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Natl. Med. 1998;4:43–49
  32. Fung PYS, Longenecker BM. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res. 1991;51:1170–1176
  33. Sikut R, Zhang K, Baeckstrom D. Distinct sub-populations of carcinoma-associated MUC1 mucins as detected by the monoclonal antibody 9H8 and antibodies against the sialyl-Lewis a and sialyl-Lewis x epitopes in the circulation of breast cancer patients. Int. J. Cancer. 1996;66:617–623
  34. Mackinnon WB, Huschtscha L, Dent K, Hancock R, Paraskeva C, Mountford CE. Correlation of cellular differentiation in human colorectal carcinoma and adenoma cell lines with metabolite profiles determined by IH magnetic resonance spectroscopy. Int. J. Cancer. 1994;59:248–261
  35. Mackinnon WB, Russel P, May GL, Mountford CE. Characterization of human ovarian epithelial tumors (ex vivo) by proton magnetic resonance spectroscopy. Int. J. Gynecol. Cancer. 1995;2:211–221
  36. Reddish MA, Helbrecht N, Almeida AF, Madiyalakan R, Suresh MR, Longenecker BM. Epitope Mapping of MAb B27.29 Within the Peptide Core of The Malignant Breast Carcinoma-Associated Mucin Antigen Coded for by the Human MUC 1 Gene. J. Tumor Marker Oncol. 1992;7:19–27
  37. Hayes DF, Bast RC, Desch CE, et al.  Tumor marker utility grading system (A framework to evaluate clinical utility of tumor markers). J. Natl. Cancer I. 1996;88:1456–1466

PII: S0959-8049(00)00396-8

European Journal of Cancer
Volume 37, Issue 3 , Pages 355-363 , February 2001

Article Tools

* Image Usage & Resolution